Using Qube 384, we profiled a panel of NaV inhibitors across species, providing valuable translational insight early in analgesic drug discovery.
Early cardiac derisking: A clinically translatable hiPSC cardiomyocyte assayAchieve action potential recordings from intrinsically paced hiPSC-CMs with Metrion’s clinically predictive hiPSC cardiomyocyte assay.
Read more about our hiPSC cardiomyocyte assay.
Using Qube 384, we profiled a panel of NaV inhibitors across species, providing valuable translational insight early in analgesic drug discovery.
We explore hNav1.9's unique fast and slow inactivation properties using Qube 384 and QPatch 48 platforms, helping to build more predictive screening assays for state-dependent inhibitors.